Literature DB >> 34182525

Clinical Significance of Composition Changes in T-cell Subpopulations After Chemotherapy in Patients With Gastric Cancer.

Min-Kyung Yeo1, Pureum Sun2, Chaeuk Chung3, Jae Ho Park4, Sun Hyung Kang4, Hee Seok Moon4, Jae Kyu Sung4, Hyun Yong Jeong4, Ju Seok Kim5.   

Abstract

BACKGROUND/AIM: New therapeutic agents and prognostic biomarkers for gastric cancer are needed. We analyzed the composition of peripheral blood T-cell subpopulations in response to chemotherapy in patients with gastric cancer. PATIENTS AND METHODS: Peripheral blood samples were collected from patients diagnosed with gastric cancer before and after chemotherapy (FOLFOX; oxaliplatin, 5-fluorouracil, and leucovorin). Peripheral blood mononuclear cells were isolated. Patients were divided into responder (n=5) and non-responder groups (n=2) based on their chemotherapy outcomes.
RESULTS: Non-responders showed lower numbers of CD4+/total cells and CD8+/total cells after chemotherapy compared to the responder group, but the difference was not significant (p=0.905, p=0.095). Naïve T, central memory T, effector memory T and effector T-cell counts differed in both groups after chemotherapy.
CONCLUSION: Changes in peripheral T-cell subpopulations after chemotherapy were confirmed in patients with gastric cancer, which may be a prognostic predictor and development of therapeutic agents.
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Peripheral T-cell subpopulation; gastric cancer; immunotherapy; prognosis

Year:  2021        PMID: 34182525     DOI: 10.21873/invivo.12519

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  1 in total

1.  Symptom burden and health-related quality of life six months after hyperbaric oxygen therapy in cancer survivors with pelvic radiation injuries.

Authors:  Grete K Velure; Bernd Müller; May Aa Hauken
Journal:  Support Care Cancer       Date:  2022-03-23       Impact factor: 3.359

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.